AUTHORS
Muhamed Baljevic, Director, Multiple Myeloma Program, Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP), Eben Lichtman2, Mitul Gandhi, MD3, Hang Quach, MBBS MD FRACP FRCPA4, Kaustav Chatterjee, MD5, Scott Cooper6, Tiancheng He7, Steve Stricker, MS, PharmD8, Anders Svensson, MD9, Dan Webster10, Jovian Yu, MD, MS, MBA11, Cesar Rodriguez Valdes, MD12
AFFILIATIONS
1 Vanderbilt University Medical Center, Nashville, Tennessee, United States
2 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
3 Virginia Cancer Specialists, US Oncology Research, Gainesville, Virginia, United States
4 St Vincent's Hospital Melbourne, University of Melbourne, Melbourne, Victoria, Australia
5 AbbVie Inc., North Chicago, Illinois, United States
6 AbbVie Inc., North Chicago, Illinois, United States
7 AbbVie Inc., North Chicago, Illinois, United States
8 AbbVie Inc., North Chicago, Illinois, United States
9 AbbVie Inc., North Chicago, Illinois, United States
10 AbbVie Inc., North Chicago, Illinois, United States
11 AbbVie Inc., North Chicago, Illinois, United States
12 Division of Hematology-Oncology, Department of Internal Medicine, Mount Sinai, New York, New York, United States
ABSTRACT
Background:
Bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) have expanded treatment options for relapsed/refractory multiple myeloma (RRMM). However, the risk of cytokine release syndrome (CRS) represents a hurdle for BsAb treatment adoption for some community and outpatient settings, impacting patient quality of life and healthcare resource utilization.
Etentamig is being developed as a next-generation, patient-centric, differentiated BCMA x CD3 bispecific T-cell engager with monthly (Q4W) dosing. Recent results from Arm C of the MONVISO study demonstrated that prophylactic Tocilizumab with Etentamig resulted in a 0% CRS incidence.
There remains a well-recognized global unmet need for less burdensome outpatient treatment options for RRMM. Continuous, digital monitoring of CRS-associated physiologic changes in the outpatient setting may provide insight into Etentamig CRS dynamics and inform outpatient management.
Objectives:
This study sought to evaluate continuous digital monitoring of vital signs for the characterization of CRS during outpatient initiation of Etentamig in patients with RRMM.
Methods:
The MONVISO study (NCT05650632) is a global, multicenter, phase 1b, open-label clinical trial. Arm C of the study (n=60) investigated outpatient initiation of Etentamig in patients with RRMM (≥2 prior lines, including exposure to proteasome inhibitors [PI], immunomodulatory drugs [IMiD], and anti-CD38). In Arm C, participants received Etentamig in cycle 1 fully outpatient (2 mg on Cycle 1 Day 1, 60 mg full dose on Cycle 1 Day 4), with eligibility criteria ensuring suitability for ambulatory management. Dexamethasone pre-medication was required prior to Etentamig dosing in Cycle 1 and Tocilizumab was administered at the discretion of the Investigator. Continuous digital monitoring (Current Health™ wearable, VivaLink FeverScout™ axillary temperature sensor) was implemented from ≥1 hour before dosing through 48 hours post–full dose, measuring temperature, heart and respiratory rate, and pulse oximetry. The study utilized standardized CRS education for patients/caregivers, protocolized escalation/intervention algorithms, and scheduled laboratory, safety, and patient-reported outcomes (PROs) and manual temperature collection. Digital vital sign data were collected, but were not visible to patients nor utilized for adverse event detection or clinical decision-making regarding CRS management during the study.
Results:
In the overall Arm C cohort (n=60), 16 subjects (27%) experienced CRS (23% grade 1 and 3% grade 2). In the digital health technology (DHT) cohort, 38 subjects participated and 8 subjects (21%) that were adherent to wearable monitoring experienced CRS (18% grade 1 and 3% grade 2). Importantly, in 100% of CRS cases, CRS-associated fevers were detected by the DHT.
In the DHT cohort, 3 CRS cases occurred after the step-up dose and 5 cases occurred after the first full dose. Mean adherence to DHT wear time in the 48 hours post infusion was 81.6% (62/76 infusions) for the upper-arm vitals monitor and 61.8% (47/76) for the adhesive axillary temperature patch. Notably, the initial detection of CRS-related fever by the DHT system occurred at a median of 82 minutes prior to clinical diagnosis of CRS (range from 180 min. before to 90 minutes after). Fevers tracked by DHT resolved to normal temperature values at a median of 4 hr., 45 min. prior to clinically determined CRS resolution (range from 12 hours, 15 min. to 0 minutes prior to clinically diagnosed CRS resolution).
Conclusions: While this study did not employ real-time data for clinical decision-making, these high-resolution data demonstrate the feasibility of digital monitoring during outpatient administration of Etentamig in patients with RRMM. These data also support the predictable signature of Etentamig-related CRS with objective physiologic vital sign parameters that may help expand access to BsAb therapy across diverse treatment settings.
DISCLOSURES
Muhamed Baljevic, Director, Multiple Myeloma Program, Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP): National Comprehensive Cancer Network - Honoraria; Targeted Oncology - Honoraria; Curio Science - Honoraria; MJH Life Sciences - Honoraria; Johnson & Johnson - Research Funding; Pfizer - Research Funding; Sanofi-Genzyme - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Parexel - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Delta-Fly Pharma - Consultancy (Includes expert testimony); Prothena - Consultancy (Includes expert testimony); Cardinal Health - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Janssen Research and Development - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Xilis Inc. - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony)